A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer (NCT04787289)
🩺 Plain-English Summary (8th-Grade Level)
A pragmatic, two armed, study comparing 2 standard doses of an anti-cancer drug called bevacizumab, given in combination with Chemotherapy. The study will be offered to ovarian cancer patients whose disease is platinum chemotherapy resistant . Higher doses of anti-cancer based drugs are not always better than lower doses and can cause more side effects without improvement of cancer. These patients will be randomly assigned either 7.5 mg/kg or 15mg/kg of bevacizumab combined with chemotherapy . Comparing these two doses will determine if the lower dose-level is non-inferior, and could lead to practice changes.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (17 items) and avoid the listed exclusions (16 items).
Location: Abbotsford Centre, BC Cancer Agency — Abbotsford British Columbia, British Columbia
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Patients with a history of other active or current malignancies that require active treatment.
- Patients with serious illness or medical conditions that might be aggravated by treatment or limit compliance including, but not limited to:
- History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements.
- Uncontrolled hypertension
- Active uncontrolled or serious infection (viral, bacterial or fungal)
- Other medical conditions that might be aggravated by study treatment
- Patients receiving concurrent treatment with other anti-cancer therapy or investigational agents.
- Neutrophils less than 1 x 10\^9 /L
- Pregnancy or breastfeeding
- Bleeding diathesis
- History of bowel obstruction or unresolved bowel obstruction (refer to the BC Cancer protocols above)
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (2 Sites)
- Abbotsford Centre, BC Cancer Agency — Abbotsford British Columbia, British Columbia
- BC Cancer - Vancouver — Vancouver, British Columbia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.